Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance

Citations Over Time

Abstract

Despite our progressive understanding of HIV type-1 (HIV-1) infection and the development of a number of antiretroviral agents to delay the onset of AIDS, there remains a need for agents with improved efficacy and safety. In particular, therapy options for treatment-experienced adult patients have been limited by the presence of drug-resistant virus, which often leads to a reduced virological response in these patients. The recently approved non-nucleoside reverse transcriptase inhibitor etravirine has demonstrated durable and superior efficacy over placebo and a favourable tolerability profile in HIV-1-infected, treatment-experienced patients, offering a valuable new therapeutic option. This review examines the clinical development and drug profile of etravirine, placing it in the context of other antiretrovirals available for treatment-experienced patients.

Related Papers

• → Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors(2010)60 cited
• → Etravirine and Rilpivirine: Nonnucleoside Reverse Transcriptase Inhibitors with Activity Against Human Immunodeficiency Virus Type 1 Strains Resistant to Previous Nonnucleoside Agents(2009)43 cited
• → HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa(2017)31 cited
• → Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India(2016)17 cited
• → Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy(2014)10 cited